Natera (NTRA) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $37.52B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Medical - Diagnostics & Research |
| Country | US | CEO | Steven Leonard Chapman |
| IPO Date | 2015-07-01 | CAGR | 47.89% |
| Employees | 6,140 | Website | www.natera.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $35.87B | P/E | -164.77 | Forward P/E | -1279.94 | PEG | — |
| P/S | 5593.49 | P/B | 7788.27 | P/CF | 65470.35 | P/FCF | 151972.73 |
| Sales | $2.50B | Sales 1Y | 36.59% | Sales 3Y | 188.18% | Sales 5Y | 456.62% |
| EPS | $-1.59 | EPS 1Y | — | EPS 3Y | — | EPS 5Y | — |
| Sales QoQ | 4.68% | EPS QoQ | -271.43% | Sales QoQ Avg | 8.58% | EPS QoQ Avg | -97.91% |
| Gross Margin | 65.16% | Operating Margin | -12.97% | Profit Margin | -9.05% | ROCE | -15.77% |
| ROA | -9% | ROE | -15% | Altman Z Score | 26.35 | Piotroski Score | 4 |
| Current Ratio | 2.96 | Quick Ratio | 2.83 | Cash Ratio | 1.95 | Op. CF Ratio | 0.07 |
| Debt/Equity | 0.14 | Debt/Assets | 0.09 | Lt Debt/Equity | 0.08 | Lt Debt/Cap. | — |
| Intrst Cov. | -38.93 | Inventory Turnover | 12.32 | Asset Turnover | 0.96 | Receivables Turnover | 5.99 |
| Enterprise Value | $35.87B | P/E Ratio | -164.77 |
| Forward P/E | -1279.94 | PEG Ratio | — |
| P/S Ratio | 5593.49 | P/B Ratio | 7788.27 |
| P/CF Ratio | 65470.35 | P/FCF Ratio | 151972.73 |
| EPS | $-1.59 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 36.59% | Gross Margin | 0.65% |
| Operating Margin | -0.13% | Profit Margin | -0.09% |
| ROE | -0.15% | ROA | -0.09% |
| ROCE | -0.16% | Current Ratio | 2.96 |
| Quick Ratio | 2.83 | Cash Ratio | 1.95 |
| Debt/Equity | 0.14 | Interest Coverage | -38.93 |
| Altman Z Score | 26.35 | Piotroski Score | 4 |
Natera (NTRA) valuation & financials
Natera (NTRA) has a market capitalization of $37.52B and trades at a price-to-earnings ratio of -164.8. It operates in the Healthcare sector (Medical - Diagnostics & Research).
Natera's revenue grew +36.6% over the last year.
Natera's next earnings report is scheduled for August 6, 2026; analysts estimate EPS of $-0.49.
Natera (NTRA) — frequently asked questions
When does Natera (NTRA) report earnings next?
Natera is expected to report earnings on August 6, 2026. Analysts estimate EPS of $-0.49.
What is Natera's market cap?
Natera (NTRA) has a market capitalization of $37.52B.
What is NTRA's P/E ratio?
Natera trades at a price-to-earnings ratio of -164.8, with trailing twelve-month EPS of $-1.59.
How fast is Natera growing?
Natera's revenue grew +36.6% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)